Patrick Hwu

33.3k total citations · 10 hit papers
200 papers, 17.4k citations indexed

About

Patrick Hwu is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Patrick Hwu has authored 200 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Oncology, 80 papers in Immunology and 77 papers in Molecular Biology. Recurrent topics in Patrick Hwu's work include Immunotherapy and Immune Responses (62 papers), CAR-T cell therapy research (62 papers) and Cancer Immunotherapy and Biomarkers (59 papers). Patrick Hwu is often cited by papers focused on Immunotherapy and Immune Responses (62 papers), CAR-T cell therapy research (62 papers) and Cancer Immunotherapy and Biomarkers (59 papers). Patrick Hwu collaborates with scholars based in United States, Australia and Italy. Patrick Hwu's co-authors include Steven A. Rosenberg, Douglas J. Schwartzentruber, Suzanne L. Topalian, James Chih‐Hsin Yang, Richard M. Sherry, Seth M. Steinberg, Leah Haworth, Claudia A. Seipp, Donald E. White and Helen X. Chen and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Patrick Hwu

195 papers receiving 17.1k citations

Hit Papers

A Randomized Trial of Bev... 1998 2026 2007 2016 2003 2017 1998 2003 2006 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
    2003 2.1k citations James Chih‐Hsin Yang, Leah Haworth et al. profile →
  2. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
    2017 1.6k citations Patrick Hwu et al. profile →
  3. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
    1998 1.5k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. profile →
  4. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
  5. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
    2006 984 citations Sharon Mavroukakis, James C. Yang et al. Clinical Cancer Research profile →
  6. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
    2003 573 citations James Chih‐Hsin Yang, Richard M. Sherry et al. Journal of Clinical Oncology profile →
  7. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma
    2002 565 citations John Toso, Vee J. Gill et al. Journal of Clinical Oncology profile →
  8. Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-6
    2004 534 citations Patrick Hwu et al. profile →
  9. NRAS mutation status is an independent prognostic factor in metastatic melanoma
    2011 528 citations Roland L. Bassett, Chaan S. Ng et al. profile →
  10. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
    2024 64 citations Leisha A. Emens, Pedro Romero et al. Journal for ImmunoTherapy of Cancer profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Patrick Hwu 10.8k 7.7k 6.6k 2.4k 2.1k 200 17.4k
Mario Sznol 13.8k 1.3× 7.8k 1.0× 5.6k 0.8× 4.3k 1.8× 1.2k 0.6× 270 19.8k
Douglas J. Schwartzentruber 8.9k 0.8× 9.8k 1.3× 4.8k 0.7× 2.1k 0.9× 2.0k 0.9× 81 16.3k
Richard M. Sherry 18.5k 1.7× 13.8k 1.8× 6.1k 0.9× 2.8k 1.2× 3.8k 1.8× 97 25.0k
Robert H. Vonderheide 15.2k 1.4× 14.2k 1.8× 6.9k 1.0× 2.4k 1.0× 1.1k 0.5× 224 25.0k
Udai S. Kammula 14.0k 1.3× 10.2k 1.3× 4.2k 0.6× 1.3k 0.6× 2.7k 1.3× 89 18.2k
Patrick Hwu 9.4k 0.9× 10.0k 1.3× 4.4k 0.7× 1.6k 0.7× 1.6k 0.8× 220 15.8k
Lawrence Fong 8.9k 0.8× 8.2k 1.1× 4.5k 0.7× 2.9k 1.2× 970 0.5× 268 16.2k
Michael A. Morse 10.1k 0.9× 6.0k 0.8× 5.1k 0.8× 2.7k 1.1× 729 0.3× 383 18.1k
Gavin P. Dunn 8.4k 0.8× 8.9k 1.2× 4.2k 0.6× 1.8k 0.8× 698 0.3× 136 16.4k
Alexander Eggermont 5.7k 0.5× 5.3k 0.7× 4.1k 0.6× 1.4k 0.6× 1000 0.5× 218 11.9k

Countries citing papers authored by Patrick Hwu

Since Specialization
Citations

This map shows the geographic impact of Patrick Hwu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Hwu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Hwu more than expected).

Fields of papers citing papers by Patrick Hwu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Hwu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Hwu. The network helps show where Patrick Hwu may publish in the future.

Co-authorship network of co-authors of Patrick Hwu

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Hwu. A scholar is included among the top collaborators of Patrick Hwu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Hwu. Patrick Hwu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guerrieri, Renato, Grant M. Fischer, Barbara Knighton, et al.. (2025). Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade. Scientific Reports. 15(1). 34352–34352.
2.
Tarhini, Ahmad A., Sandra J. Lee, William A. LaFramboise, et al.. (2025). Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Clinical Cancer Research. 31(15). 3249–3258.
3.
Emens, Leisha A., Pedro Romero, Ana C. Anderson, et al.. (2024). Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. Journal for ImmunoTherapy of Cancer. 12(6). e009063–e009063. 64 indexed citations breakdown →
4.
Chaudhri, Apoorvi, Gregory Lizée, Patrick Hwu, & Kunal Rai. (2024). Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment. Cancer Research. 84(7). 965–976. 7 indexed citations
5.
Chen, James L., Aakrosh Ratan, Martin D. McCarter, et al.. (2023). The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors. Cancers. 15(20). 4913–4913. 5 indexed citations
6.
Fix, Samantha M., Marie‐Andrée Forget, Donastas Sakellariou-Thompson, et al.. (2022). CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. Journal for ImmunoTherapy of Cancer. 10(7). e003750–e003750. 29 indexed citations
7.
Zahid, Mohammad U., Jennifer M. Binning, Bryan Q. Spring, et al.. (2022). Rethinking the immunotherapy numbers game. Journal for ImmunoTherapy of Cancer. 10(7). e005107–e005107. 12 indexed citations
8.
Ascierto, Paolo A., Carlo Bifulco, Fortunato Ciardiello, et al.. (2021). Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy). Journal of Translational Medicine. 19(1). 238–238. 3 indexed citations
9.
Tsimberidou, Apostolia M., David S. Hong, Jennifer J. Wheler, et al.. (2019). Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. Journal of Hematology & Oncology. 12(1). 145–145. 46 indexed citations
10.
Bentebibel, Salah-Eddine, Michael E. Hurwitz, Chantale Bernatchez, et al.. (2019). A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discovery. 9(6). 711–721. 169 indexed citations
11.
Hu, Jiemiao, Chantale Bernatchez, Liangfang Zhang, et al.. (2017). Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research. 5(4). 300–311. 21 indexed citations
12.
Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574. 158 indexed citations
13.
Bucheit, Amanda D., Guo Chen, Alan Siroy, et al.. (2014). Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAF V600 Mutations. Clinical Cancer Research. 20(21). 5527–5536. 109 indexed citations
14.
Davies, Michael A., Patricia S. Fox, Nicholas E. Papadopoulos, et al.. (2012). Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research. 18(4). 1120–1128. 39 indexed citations
15.
Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations
16.
Hong, David S., Luis M. Vence, Gerald S. Falchook, et al.. (2012). BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. Clinical Cancer Research. 18(8). 2326–2335. 82 indexed citations
17.
Chang, David Z., Ying Ma, Baoan Ji, et al.. (2011). Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 17(22). 7015–7023. 119 indexed citations
18.
Woodman, Scott E., Jonathan C. Trent, Katherine Stemke‐Hale, et al.. (2009). Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics. 8(8). 2079–2085. 141 indexed citations
19.
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377. 1234 indexed citations breakdown →
20.
Toso, John, Vee J. Gill, Patrick Hwu, et al.. (2002). Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma. Journal of Clinical Oncology. 20(1). 142–152. 565 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mario Sznol Breakdown of academic impact, for papers by Douglas J. Schwartzentruber Breakdown of academic impact, for papers by Richard M. Sherry Breakdown of academic impact, for papers by Robert H. Vonderheide Breakdown of academic impact, for papers by Udai S. Kammula Breakdown of academic impact, for papers by Patrick Hwu Breakdown of academic impact, for papers by Lawrence Fong Breakdown of academic impact, for papers by Michael A. Morse Breakdown of academic impact, for papers by Gavin P. Dunn Breakdown of academic impact, for papers by Alexander Eggermont
Rankless by CCL
2026